Drug intelligence / Profile preview

[11C]diprenorphine

Development stage: Unknown
Modality: Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

[11C]diprenorphine is a positron emission tomography (PET) radioligand used to study the opioid receptor system in vivo. It is synthesized by carbon-11 methylation of diprenorphine and acts as a non-selective antagonist at all opioid receptor subtypes (mu, kappa, and delta). With a short half-life due to the carbon-11 isotope, it allows for quantitative imaging of opioid receptors in research settings.

Other names: 6-O-methyl-11C]diprenorphine

Targets

KOR (Kappa opioid receptor)MOR (Mu opioid receptor)DOR (Opioid Receptor Delta 1)

Beyond the preview

Go deeper on [11C]diprenorphine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on [11C]diprenorphine.

Explore the full profile